Literature DB >> 18292289

Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB.

Liang Yu1, Abdalla J Mohamed, Oscar E Simonson, Leonardo Vargas, K Emelie M Blomberg, Bo Björkstrand, H Jose Arteaga, Beston F Nore, C I Edvard Smith.   

Abstract

Bruton tyrosine kinase (Btk) is critical for B-cell development. Btk regulates a plethora of signaling proteins, among them nuclear factor-[kappa]B (NF-kappaB). Activation of NF-kappaB is a hallmark of B cells, and NF-kappaB signaling is severely compromised in Btk deficiency. We here present strong evidence indicating that NF-kappaB is required for efficient transcription of the Btk gene. First, we found that proteasome blockers and inhibitors of NF-kappaB signaling suppress Btk transcription and intracellular expression. Similar to Btk, proteasome inhibitors also reduced the expression of other members of this family of kinases, Itk, Bmx, and Tec. Second, 2 functional NF-kappaB-binding sites were found in the Btk promoter. Moreover, in live mice, by hydrodynamic transfection, we show that bortezomib (a blocker of proteasomes and NF-kappaB signaling), as well as NF-kappaB binding sequence-oligonucleotide decoys block Btk transcription. We also demonstrate that Btk induces NF-kappaB activity in mice. Collectively, we show that Btk uses a positive autoregulatory feedback mechanism to stimulate transcription from its own promoter via NF-kappaB.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18292289     DOI: 10.1182/blood-2007-10-121137

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

1.  SDF1α-induced chemotaxis of JAK2-V617F-positive cells is dependent on Bruton tyrosine kinase and its downstream targets PI3K/AKT, PLCγ1 and RhoA.

Authors:  Subbaiah Chary Nimmagadda; Stephanie Frey; Peter Müller; Denise Wolleschak; Sönke Weinert; Ulrich Keller; Bärbel Edelmann; Thomas Fischer
Journal:  Haematologica       Date:  2019-02-14       Impact factor: 9.941

Review 2.  The tumor microenvironment shapes hallmarks of mature B-cell malignancies.

Authors:  K H Shain; W S Dalton; J Tao
Journal:  Oncogene       Date:  2015-02-02       Impact factor: 9.867

Review 3.  BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.

Authors:  M Spaargaren; M F M de Rooij; A P Kater; E Eldering
Journal:  Oncogene       Date:  2014-06-23       Impact factor: 9.867

4.  Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells.

Authors:  Y Zhong; D El-Gamal; J A Dubovsky; K A Beckwith; B K Harrington; K E Williams; V M Goettl; S Jha; X Mo; J A Jones; J M Flynn; K J Maddocks; L A Andritsos; D McCauley; S Shacham; M Kauffman; J C Byrd; R Lapalombella
Journal:  Leukemia       Date:  2014-01-13       Impact factor: 11.528

5.  Bruton's tyrosine kinase regulates Shigella flexneri dissemination in HT-29 intestinal cells.

Authors:  Ana-Maria Dragoi; Arthur M Talman; Hervé Agaisse
Journal:  Infect Immun       Date:  2012-12-10       Impact factor: 3.441

6.  Development of B-lineage predominant lentiviral vectors for use in genetic therapies for B cell disorders.

Authors:  Blythe D Sather; Byoung Y Ryu; Brigid V Stirling; Mikhail Garibov; Hannah M Kerns; Stéphanie Humblet-Baron; Alexander Astrakhan; David J Rawlings
Journal:  Mol Ther       Date:  2010-12-07       Impact factor: 11.454

7.  F-box protein 10, an NF-κB-dependent anti-apoptotic protein, regulates TRAIL-induced apoptosis through modulating c-Fos/c-FLIP pathway.

Authors:  R Ge; Z Wang; Q Zeng; X Xu; A F Olumi
Journal:  Cell Death Differ       Date:  2011-01-21       Impact factor: 15.828

8.  Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.

Authors:  Baohua Sun; Bhavin Shah; Warren Fiskus; Jun Qi; Kimal Rajapakshe; Cristian Coarfa; Li Li; Santhana G T Devaraj; Sunil Sharma; Liang Zhang; Michael L Wang; Dyana T Saenz; Stephanie Krieger; James E Bradner; Kapil N Bhalla
Journal:  Blood       Date:  2015-08-07       Impact factor: 22.113

9.  B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia.

Authors:  Hannah M Kerns; Byoung Y Ryu; Brigid V Stirling; Blythe D Sather; Alexander Astrakhan; Stephanie Humblet-Baron; Denny Liggitt; David J Rawlings
Journal:  Blood       Date:  2010-01-21       Impact factor: 22.113

10.  Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.

Authors:  Zheng Hu; Xiao-Fen Pan; Fu-Qun Wu; Li-Yuan Ma; Da-Peng Liu; Ying Liu; Ting-Ting Feng; Fan-Yi Meng; Xiao-Li Liu; Qian-Li Jiang; Xiao-Qin Chen; Jing-Lei Liu; Ping Liu; Zhu Chen; Sai-Juan Chen; Guang-Biao Zhou
Journal:  PLoS One       Date:  2009-07-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.